Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

RJ. Moots, RM. Xavier, CC. Mok, MU. Rahman, WC. Tsai, MH. Al-Maini, K. Pavelka, E. Mahgoub, S. Kotak, J. Korth-Bradley, R. Pedersen, L. Mele, Q. Shen, B. Vlahos,

. 2017 ; 12 (4) : e0175207. [pub] 20170427

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030853

OBJECTIVE: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported outcomes. METHODS: This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult patients with RA treated continuously for 6-24 months with ETN, ADL, or IFX. ADA and trough drug concentrations were measured by independent assays ≤2 days before the next scheduled dose. Efficacy measurements included Disease Activity Score 28-joint count (DAS28), low disease activity (LDA), remission, and erythrocyte sedimentation rate (ESR). Targeted medical histories of injection site/infusion reactions, serum sickness, and thromboembolic events were collected. RESULTS: Baseline demographics of the 595 patients (ETN: n = 200; ADL: n = 199; IFX: n = 196) were similar across groups. The mean duration of treatment was 14.6, 13.5, and 13.1 months for ETN, ADL, and IFX, respectively. All ETN-treated patients tested negative for ADA, whereas 31.2% and 17.4% patients treated with ADL and IFX, respectively, tested positive. In ADL- or IFX-treated patients, those with ADA had significantly lower trough drug concentrations. There were negative correlations between trough drug levels and both CRP and ESR in ADL- and IFX-treated patients. DAS28-ESR LDA and remission rates were higher in patients without ADA. The rate of targeted medical events reported was low. CONCLUSION: ADA were detected in ADL- and IFX-treated but not ETN-treated patients. Patients without ADA generally showed numerically better clinical outcomes than those with ADA. TRIAL REGISTRATION: This study was registered on www.ClinicalTrials.gov (NCT01981473).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030853
003      
CZ-PrNML
005      
20171025122753.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0175207 $2 doi
035    __
$a (PubMed)28448562
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Moots, Robert J $u Aintree University Hospital, University of Liverpool, Liverpool, United Kingdom.
245    14
$a The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study / $c RJ. Moots, RM. Xavier, CC. Mok, MU. Rahman, WC. Tsai, MH. Al-Maini, K. Pavelka, E. Mahgoub, S. Kotak, J. Korth-Bradley, R. Pedersen, L. Mele, Q. Shen, B. Vlahos,
520    9_
$a OBJECTIVE: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported outcomes. METHODS: This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult patients with RA treated continuously for 6-24 months with ETN, ADL, or IFX. ADA and trough drug concentrations were measured by independent assays ≤2 days before the next scheduled dose. Efficacy measurements included Disease Activity Score 28-joint count (DAS28), low disease activity (LDA), remission, and erythrocyte sedimentation rate (ESR). Targeted medical histories of injection site/infusion reactions, serum sickness, and thromboembolic events were collected. RESULTS: Baseline demographics of the 595 patients (ETN: n = 200; ADL: n = 199; IFX: n = 196) were similar across groups. The mean duration of treatment was 14.6, 13.5, and 13.1 months for ETN, ADL, and IFX, respectively. All ETN-treated patients tested negative for ADA, whereas 31.2% and 17.4% patients treated with ADL and IFX, respectively, tested positive. In ADL- or IFX-treated patients, those with ADA had significantly lower trough drug concentrations. There were negative correlations between trough drug levels and both CRP and ESR in ADL- and IFX-treated patients. DAS28-ESR LDA and remission rates were higher in patients without ADA. The rate of targeted medical events reported was low. CONCLUSION: ADA were detected in ADL- and IFX-treated but not ETN-treated patients. Patients without ADA generally showed numerically better clinical outcomes than those with ADA. TRIAL REGISTRATION: This study was registered on www.ClinicalTrials.gov (NCT01981473).
650    _2
$a adalimumab $x škodlivé účinky $x imunologie $x farmakologie $x terapeutické užití $7 D000068879
650    _2
$a protilátky $x imunologie $7 D000906
650    _2
$a antirevmatika $x imunologie $x farmakologie $x terapeutické užití $7 D018501
650    _2
$a revmatoidní artritida $x farmakoterapie $x imunologie $7 D001172
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a etanercept $x škodlivé účinky $x imunologie $x farmakologie $x terapeutické užití $7 D000068800
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a infliximab $x škodlivé účinky $x imunologie $x farmakologie $x terapeutické užití $7 D000069285
650    _2
$a internacionalita $7 D038622
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a bezpečnost $7 D012449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Xavier, Ricardo M $u Hospital de Clinicas, Porto Alegre, Brazil.
700    1_
$a Mok, Chi Chiu $u Tuen Mun Hospital, Hong Kong, People's Republic of China.
700    1_
$a Rahman, Mahboob U $u Pfizer, Collegeville, Pennsylvania, United States of America.
700    1_
$a Tsai, Wen-Chan $u Kaohsiung Medical University, Kaohsiung City, Taiwan.
700    1_
$a Al-Maini, Mustafa H $u Mafraq Hospital, Abu Dhabi, United Arab Emirates. $7 gn_A_00004575
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic.
700    1_
$a Mahgoub, Ehab $u Pfizer, Collegeville, Pennsylvania, United States of America.
700    1_
$a Kotak, Sameer $u Pfizer, Collegeville, Pennsylvania, United States of America.
700    1_
$a Korth-Bradley, Joan $u Pfizer, Collegeville, Pennsylvania, United States of America.
700    1_
$a Pedersen, Ron $u Pfizer, Collegeville, Pennsylvania, United States of America.
700    1_
$a Mele, Linda $u Pfizer, Collegeville, Pennsylvania, United States of America.
700    1_
$a Shen, Qi $u Pfizer, Collegeville, Pennsylvania, United States of America.
700    1_
$a Vlahos, Bonnie $u Pfizer, Collegeville, Pennsylvania, United States of America.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 4 (2017), s. e0175207
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28448562 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025122835 $b ABA008
999    __
$a ok $b bmc $g 1254446 $s 991880
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 4 $d e0175207 $e 20170427 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20171025
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace